GF Fund Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

GF Fund Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,818	Closed	-$10.6K	–	675
2025 Q3	$10.6K	Buy	+7,818	New	+$8.87K	﹤0.01%	551

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

GF Fund Management's LXRX Position: Q4 2025 in Review

GF Fund Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2025, closing a stake of 7,818 shares — an estimated $10.6K sold.

GF Fund Management first reported a position in LXRX in Q3 2025 and held it in 1 quarter. The position peaked at $10.6K in Q3 2025. 125 funds tracked by Wall St. Rank hold LXRX as of Q4 2025.

GF Fund Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
GF Fund Management sold 7,818 Lexicon Pharmaceuticals shares in Q4 2025, an estimated $10.6K.
GF Fund Management first reported a position in Lexicon Pharmaceuticals in Q3 2025 and held it in 1 quarter.
GF Fund Management's Lexicon Pharmaceuticals position peaked at $10.6K in Q3 2025.
125 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2025.

Based on GF Fund Management's 13F filing for Q4 2025, filed 27 Jan 2026.